Alnylam Stock Rebounds as Raymond James Upgrades to 'Strong Buy'

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares rose in pre-market trading after Raymond James upgraded the stock to Strong Buy from Outperform, sparking renewed investor interest after a significant selloff. The firm set a new price target of $420 per share, suggesting substantial upside from its recent lows.

Analyst Sees Oversold Opportunity

The upgrade from Raymond James is based on the view that Alnylam's stock has been excessively punished following its second-quarter earnings report. According to the analyst, the recent price decline fails to account for the long-term value of the company's drug pipeline and collaboration programs.

Other Wall Street firms have expressed similar views, seeing the stock's pullback as a buying opportunity. Scotiabank issued a positive forecast, and UBS also provided constructive commentary on August 2. While Barclays maintained its Overweight rating, it trimmed its price target to $450 from $527, citing a more cautious outlook on near-term dynamics for the company's ATTR franchise.

Context of the Recent Selloff

The positive analyst sentiment follows a difficult period for Alnylam's stock, which had fallen approximately 35% since early July. The decline was triggered by the company's Q2 earnings report, which included a guidance reduction for its transthyretin amyloidosis (ATTR) franchise.

Ad

This prolonged selling pressure pushed the stock near its 52-week low of $197.81. Despite the recent rebound, shares remain down roughly 48% year-to-date, sharply underperforming the broader market.

Market Reaction

In response to the upgrade, Alnylam shares gained 1.7% in pre-open trading, reaching $209.10. The move was supported by a positive broader market environment, with major indices like the S&P 500 and Dow Jones Industrial Average also trading higher.

The consensus among analysts is that the steep selloff created an asymmetric risk-reward profile, providing a catalyst for investors to reconsider the stock at its current valuation.